Dynamic Changes in Pancreatic Endocrine Cell Abundance, Distribution, and Function in Antigen-Induced and Spontaneous Autoimmune Diabetes

Klaus Pechhold¹, MD, Xiaolong Zhu, PhD¹, Victor S. Harrison¹, Janet Lee¹, Sagarika Chakrabarty¹³, PhD, Kerstin Koczwara, PhD¹⁴, Oksana Gavrilova, PhD² & David M. Harlan, MD¹.

¹Diabetes Branch, ²Mouse Metabolism Core, NIDDK NIH, Bethesda, MD, USA. Present address: ³NEI, NIH, Bethesda, MD, USA, ⁴Institut für Diabetesforschung - Forschergruppe Diabetes e.V. - am Helmholtz Zentrum Muenchen, Germany

Address correspondence to:
Klaus Pechhold, MD
NIDDK-Diabetes Branch, NIH
10 Center Drive
Bldg 10-CRC, Room 5W-5888
Bethesda, MD  20892, USA.
E-mail: KlausP@intra.NIDDK.NIH.gov
Alt: pechhold@cavtel.net


Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
ABSTRACT

Objective: Insulin deficiency in type 1 diabetes and in rodent autoimmune diabetes models is caused by β-cell specific killing by autoreactive T cells. Less is known about β-cell numbers and phenotype remaining at diabetes onset, and the fate of other pancreatic endocrine cellular constituents.

Research Design and Methods: We applied multicolor flow cytometry, confocal microscopy and immunohistochemistry, supported by quantitative (q)RT-PCR, to simultaneously track pancreatic endocrine-cell frequencies and phenotypes during the T cell-mediated β-cell destructive process using two independent autoimmune diabetes models, an inducible autoantigen-specific model and the spontaneously diabetic NOD mouse.

Results: The proportion of pancreatic insulin$^+$ β-cells to glucagon$^+$ α-cells was about 4:1 in non-diabetic mice. Islets isolated from newly diabetic mice exhibited the expected severe β-cell depletion accompanied by phenotypic β-cell changes (i.e. hypertrophy and degranulation), but also revealed a substantial loss of α-cells, that was further confirmed by quantitative immunohistochemistry. While maintaining normal randomly-timed serum glucagon levels, newly diabetic mice displayed an impaired glucagon secretory response to non-insulin-induced hypoglycemia.

Conclusions: Systematically applying multicolor flow cytometry and immunohistochemistry to track declining β-cell numbers in recently diabetic mice revealed an altered endocrine cell composition, that is consistent with a prominent and unexpected islet α-cell loss. These alterations were observed in induced and spontaneous autoimmune diabetes models, became apparent at diabetes onset, and differed markedly within islets compared to sub-islet-sized endocrine cell clusters and among pancreatic lobes. We propose that these changes are adaptive in nature, possibly fueled by worsening glycemia and regenerative processes.
While much has been learned about β-cell development, and β-cell biology and function in vitro (using isolated pancreatic islets), studies designed to examine β-cell phenotype in vivo have suffered from technical limitations. For instance, currently available techniques to quantify pancreatic β-cell mass rely upon laborious histomorphometric techniques(1), or upon assumptions that β-cell mass correlates with β-cell function (stimulated C-peptide release(2)), or total pancreatic insulin content(3;4). Further, quantifying the various endocrine islet cellular constituents by staining for the hormones produced, i.e. glucagon by α-cells, insulin by β-cells, somatostatin by δ-cells, and pancreatic polypeptide by PP-cells, has to date been challenging, relying again mostly on histomorphometry, and automated image processing setups typically allow only single parameter analysis(5;6).

While preparative fluorescence-activated cell sorting of islet β-cells has been attempted(7-10), wider application has been limited by the lack of islet endocrine cell surface markers and insufficient resolution by autofluorescence, especially in species other than rat(11). Fluorescence reagents with islet granule affinity to identify β-cells in both mice(12) and humans(13) have limited utility presumable because β-cells are degranulated by hyperglycemia. Other methods, such as qRT-PCR and analytical multicolor/-parameter flow cytometry, capable of precise phenotypic and functional assessment, have been hampered by both the notorious difficulty to reliably prepare pancreatic RNA(14), and the fact that the pancreas is a heterogeneous organ comprised of irregularly intermixed exocrine and endocrine tissues. Even so-called “purified” isolated pancreatic islets from naïve mice (or other mammals) represent a multitude of specialized cell types(15), which is further complicated in animals with autoimmune diabetes when abundant inflammatory cells invade the islets(16).

Recognizing these limitations, we adapted flow cytometry techniques for pancreatic studies, and together with qRT-PCR, confocal immunofluorescence microscopy and quantitative immunohistochemistry, characterized the pancreatic endocrine islet cell components in naïve and recently diabetic mice. We now report that pancreatic islets isolated from mice developing T cell-mediated β-cell specific autoimmune diabetes demonstrate an unexpected glucagon α-cell loss roughly commensurate with the expected β-cell loss.

**RESEARCH DESIGN AND METHODS**

**Mice.** Rat-insulin promoter (Rip) lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) x Rip-CD80 bitransgenic mice (17), and NOD, and fully backcrossed NOD-Rag1-null or NOD-SCID mice (both from Jackson Labs), were used as autoimmune diabetes models and controls, respectively. GP-specific, T cell receptor (TCR) transgenic mice (p14 strain(18), Rag1-null), were used as a source of monoclonal, β-cell-specific CD8+ T cells. All mice were housed at the Division of Veterinary Resources, NIH, in accordance with the guidelines set forth by the Committee on the Care and Use of Laboratory Animals on a protocol approved by the Animal Care and Use Committee of the NIDDK.

**CD8+ T cell purification and in vitro T cell activation.** TCR-transgenic CD8+ T cells (P14-strain, Rag1-null) were purified by immunodepleting spleen and lymph node cells expressing I-A^b^, CD11b, and NK1.1, yielding cells that were 86-95% CD8+ T cells. These cells (0.5*10^6/cm^2) were stimulated for 3-4 days in the presence of IFNγ-pretreated fibroblasts incubated with the GP agonist peptide (LCMV-GP aa 33-41 at
0.1 µM for 1h). Cultures were supplemented with IL-2 (2 ng/ml) after 48h. On day 3 of culture > 98% of viable cells were CD8+TCR-tg+ by flow cytometry (data not shown).

**Diabetes induction and diagnosis.** We have studied a transgenic mouse model of immune mediated β-cell destruction and diabetes that relies on the mouse β-cells expressing the LCMV GP under the control of the rat insulin promoter (Rip). If such mice are infected with LCMV, the anti-viral immune response also leads to fulminant diabetes. We have modified that system by creating bi-transgenic mice such that their β-cells also specifically express the T cell costimulatory ligand CD80 (4). These mice are highly susceptible to autoimmune β-cell destruction induced by immunizing with the GP antigen, a model system we’ve named experimental autoimmune diabetes (EAD)(17). For these studies, we adoptively transferred in vitro activated LCMV-GP specific cytotoxic T lymphocytes (CTLs, 10⁶/mouse) to the RIP-CD80-GP recipients. This EAD system initiates a slowly progressive anti-β-cell specific immune destructive process such that diabetes develops 53±9 days after CTL transfer. About 4 weeks following CTL transfer, non-diabetic mice were checked daily for diabetes development, indicated by glycosuria and confirmed when blood glucose readings were greater than 14 mM.

**Islet isolation and islet cell flow cytometry.** Pancreatic islets were isolated by standard techniques. Briefly, pancreata were inflated via bile duct cannulation and retrograde pancreatic duct injection of 3-4 ml of ice-cold collagenase type V (1 mg/ml in HBSS). Following digestion (37°C, 14 min), pancreata were dispersed by aspirating through a 14G needle, filtered through a metal strainer (0.8 mm), subjected to buoyant density gradient centrifugation (14-15% Optiprep, Accurate Chemicals, Westbury, NY). After islets were carefully picked, the remaining viable pancreatic cells were also collected. These cells containing sub-islet-sized endocrine clusters and single endocrine cells, were termed “islet-depleted cells”.

Isolated islets (and islet-depleted cells) were dissociated into a single cell suspension by gentle pipeting after washing in 2 mM EDTA/PBS, and incubating for 10 min at ambient temperature in Ca²⁺-free phosphate buffered saline (PBS) supplemented with 0.025% trypsin. Dissociated islet cells prepared from prediabetic or diabetic mice were stained for CD45 to identify infiltrating lymphocytes, followed by washing, immediate fixation, and permeabilization (4% paraformaldehyde [PFA], 0.1% saponin/PBS, 30 min). After removing PFA by washing in 0.1% saponin/1% bovine serum albumin (BSA)/PBS, islet cells were stained intracytoplasmically for 30 min with antibodies to insulin (guinea pig, DAKO), pancreatic polypeptide (rabbit, LabVision, Fremont, CA), and two mouse IgG1 monoclonal antibodies specific for glucagon (K79bB10, Sigma) and somatostatin (SOM018, antibody core facility, Beta Cell Biology Consortium, Denmark). Simultaneous staining using both mouse IgG1 antibodies required Invitrogen’s Zenon (pre)labeling technology (Pacific Blue, AlexaFluor488). Highly cross-absorbed, second-step polyclonal antibodies, anti-guinea pig-Cy5, and anti-rabbit-PE, were from Jackson ImmunoResearch. After the final wash in 1%BSA/saponin, cells were post-fixed in 1% PFA and acquired using a CyAn ADP flowcytometer (Beckman-Coulter) using Summit V 4.3 Software. Electronic gating was set to include viable cells on the basis of forward vs. side scatter. The doublet-exclusion gating setup diminished non-dissociated islet cell couplets on the basis of pulse width vs. total signal area (linear scale) by approximately 20-fold, yet did not significantly alter the relative endocrine cell
frequencies and the calculated cell ratios (Online Appendix Fig. 1).

Immunofluorescence and Immunohistochemistry. Consecutive, formalin-fixed paraffin embedded (FFPE) sections (6 µm) were hematoxylin and eosin (H&E)-stained or subjected to immunostaining. Briefly, after blocking with 2% BSA/1% donkey serum and blocking reagent (M.O.M. kit, Vector, Burlingame, CA), primary antibodies (same as described for flow cytometry above, except for the rabbit-anti-glucagon antibody [DAKO]), were reacted overnight at 4°C, washed three times (5 min, PBS 0.1% BSA, 0.1% Tween 20), then stained for 1 h using anti-guinea-pig-Cy3 (Jackson ImmunoResearch), anti-rabbit-AlexaFluor488 and anti-mouse-AlexaFluor647 (Invitrogen) polyclonal antibodies, and counterstained with DAPI (5 min). Fluorescence analysis was performed on a Zeiss LSM 510 confocal microscope using Zeiss LSM 510 Meta software (Carl Zeiss Microimaging, Thornwood, NY).

For immunohistochemistry, tissue was weighed, spread on filter paper and immediately fixed in 10% formalin. FFPE sections were antibody-stained for insulin (DAKO) or glucagon (Sigma) as above, then reacted with DAB staining kits (Vector Labs), and counterstained with H&E. Sections had an average tissue area of 72mm² (63mm² for diabetic pancreata), and the cumulative tissue area was scored from 3-7 sections spatially separated by 200 µm (surface area range studied: 154mm² - 648mm² per pancreas). Slides were scanned and analyzed using the Aperio Scanscope CS with Aperio ImageScope Software (Aperio Technologies, Inc., Vista, CA). The insulin⁺ β-cell and glucagon⁺ α-cell mass was calculated from the sections by fractional cell staining over total pancreas area for insulin⁺ and glucagon⁺ cells, respectively.

Stimulated glucagon secretion and quantification. Glucagon secretory responses to 2-deoxy-glucose (2-DG) were carried out as described(19). Briefly, 200 µl retroorbital blood was collected from newly diabetic and age- and gender-matched naive non-diabetic Rip-CD80+GP+ mice. After fasting the animals overnight, 2 additional blood samples were taken from each mouse before and, as a terminal procedure, 15 min after injecting the glucose analog 2-DG (500 mg/kg, i.p.). Serum was collected and stored frozen at -70°C. Serum glucagon concentrations were determined using RIA (Millipore, St. Charles, MO).

Statistical analysis. An independent Student’s T Test (one-tailed) was chosen to test the significance of deviations between data sets (endocrine cell numbers or ratios). All data were displayed as mean±SEM.

RESULTS

While hormone-producing cells can be visualized by multicolor immunofluorescence (Fig.1A), we sought to more objectively quantify isolated pancreatic islets’ endocrine cell frequencies using intracytoplasmic, multicolor flow cytometry to simultaneously detect insulin⁺, glucagon⁺, somatostatin⁺, and in some cases pancreatic polypeptide⁺ cells. Fig.1B and Online Appendix Fig.1 illustrate the detailed multiparameter flow cytometry results of an islet cell suspension from naive C57BL/6 mice. We observed no overlap between the various endocrine cell subsets thus confirming mature endocrine cells’ known lineage separation (i.e. each endocrine cell produces only one hormone). Artifactual dual-hormone staining resulting from heterogeneous endocrine cell couplets was eliminated by routinely applying doublet-exclusion gating strategies. We validated the flow cytometry technique by comparing adult C57BL/6 mouse endocrine cell subset frequencies determined using flow cytometry and immunofluorescence and obtained quite concordant results (Fig.1C) that are also consistent with published data(20;21).
Next, using our β-cell antigen-specific EAD model(17), we tracked insulin+ endocrine cell optical properties by flow cytometry, and their abundance by immunofluorescence or -histochemistry, flow cytometry and qRT-PCR during the islet inflammatory process leading to diabetes. Flow cytometry revealed markedly altered optical and staining properties displayed by the insulin-staining β-cells remaining at diabetes onset (Fig.2). Of particular note, some but not all β-cells remaining in diabetic mice are larger (or hypertrophic) compared to naïve mouseβ -cells (Fig.2A, red dots). In addition, virtually all diabetic mouse β-cells displayed reduced granularity (i.e. decreased side scatter, Fig.2B) strongly suggesting a diminished cytoplasmic insulin granule content (degranulation). Coincident with these optical changes, we found that diabetic mouse β-cells’ insulin staining intensity was less than that observed from naïve mouseβ -cells. To quantify this decline in individual β-cell insulin content we found that non-diabetic mouse β-cell insulin staining was ~30 fold greater than non-specific cellular fluorescence, while recently diabetic mice had only ~10 fold higher insulin+ staining over background (Fig.2C). This phenomenon was previously suspected (22), but could not be objectively quantified using conventional immunofluorescence.

We also examined the fate of other endocrine cell subsets in both healthy naïve mice (Fig.3A-C) and in mice with recent onset diabetes (Fig.3D-F). As expected, healthy, naïve Rip-CD80+GP+ bi-transgenic mice closely resembled C57BL/6 mice, both by immunofluorescence (Fig.3A,B) and by flow cytometry (Fig.3C). In contrast, heavily immune cell-infiltrated islets from diabetic Rip-CD80+GP+ mice revealed a distorted picture (Fig. 3E-F). As the islets were infiltrated with mononuclear immune cells, the endocrine cells were scattered, and reduced in number (Fig.3E). We were surprised to observe however that the residual endocrine cell frequency (suggested by immunofluorescence and quantified by flow cytometry, Fig.3F), was not consistent with a selective insulin+ β-cell loss. Rather, glucagon+ α-cell numbers decreased commensurate with the insulin+ β-cell numbers. Indeed, while we expected to find the insulin+/glucagon+ cell ratio substantially reduced in diabetic mice, that cell ratio calculated using the flow cytometry technique often increased suggesting that glucagon+ cell numbers fell even more than insulin+ cell numbers.

Previous reports employing immunohistochemistry to study the pancreas in rodents undergoing acute β-cell injury, e.g. following streptozotocin administration (23;24), or spontaneous autoimmune islet destruction (25-27), have suggested that residual pancreatic endocrine cells in diabetic animals are comprised primarily of glucagon+ and/or somatostatin+ cells. All such studies however have evaluated mice with near “end stage” diabetes while the EAD model allows us to better control both the initiation and the kinetics of the β-cell killing. We employed several independent techniques, to comprehensively examine pancreatic endocrine cell composition in EAD mice with recent onset diabetes. As shown in Fig.4 A,B, we determined insulin+/glucagon+ cell ratios from naïve and diabetic mice by flow cytometry and by immunofluorescence. Dissociated islet cells isolated from healthy control animals then analyzed by flow cytometry had an insulin+/glucagon+ cell ratio of 4.9 (n=9), which was comparable to immunofluorescence histology (ratio 4.7, n=3). In contrast, islets analyzed from diabetic animals revealed a markedly increased insulin+/glucagon+ cell ratio when analyzed by flow cytometry (9.8, n=11) compared to immunofluorescence (4.2, n=9). While flow cytometry determines relative frequencies of islet cell subsets with a high
fidelity, its translation into absolute cell numbers per pancreas has not been possible. Therefore we used quantitative immunohistochemistry on multiple sections throughout the whole pancreas in recently diabetic mice to determine changes in absolute β- and α-cell numbers at diabetes onset. As shown in Fig. 4C (left panel), recently diabetic Rip-CD80+GP+ bi-transgenic mice revealed the expected β-cell loss (an approximate 76% decrease relative to the healthy control animals), but also a corresponding depletion of α-cells (73% decrease, Fig.4D, left panel), each change is statistically significant (p<0.001). To test if the observed α-cell loss was unique to our EAD model, we extended our study to include the NOD mouse. As shown in the right hand panels of Fig 4C,D, a comparable pattern was observed in pancreas sections from newly diabetic NOD mice (age of diabetes onset: 18.2±1.8 weeks) when compared to similarly aged, female NOD-Rag1-null mice (13.4 weeks). Of note however, non-diabetic NOD mice had about half as many total β- and α-cells compared to the Rip-CD80+GP+ bi-transgenic mice, and at diabetes onset, the NOD mice were more severely β-cell-depleted than EAD mice. That is, diabetic NOD mice had about 90% of the β-cells (Fig4C, right panel). These changes were highly statistically significant (p<0.001). In the NOD mice, the α-cell depletion was less severe (58% or 2.4 fold, Fig.4D, right panel) and with p=0.026 did not reach the same high statistical significance we observed in the EAD model. The greater β-cell loss compared to α-cell loss in diabetic NOD mice resulted in a moderately reduced insulin+/glucagon+ cell ratio (1.34±0.28, n=7). For instance, Fig. 5 shows representative flow cytometry analyses from islet cells taken from diabetic (middle panel), non-diabetic (top panel), and NOD-SCID mice (lower panel). We conclude that both Rip-CD80+GP+ and NOD mice with severe insulin-deficiency caused by T cell mediated β-cell killing, also lose many α-cells such that shortly after diabetes onset the insulin+/glucagon+ cell ratio is actually maintained or increased in many Rip-CD80+GP+ mice, and only moderately reduced in NOD mice, despite a more profound β-cell loss in the latter strain.

Next, we asked whether this discrepancy could be attributed, in part, to differential endocrine cell subset distribution in large islets compared to smaller, sub-islet-sized endocrine clusters which are scattered throughout the pancreas. In the EAD model, during the autoimmune process such small endocrine cell clusters are characteristically surrounded by a marked leukocytic infiltration. We “scored” endocrine cells using immunofluorescence microscopy (Fig. 6A) and arbitrarily grouped the results into those from small clusters (< 30 endocrine cells/islet cross-section, which calculates to an islet diameter as small as 50-70 µm, depending on the level of lymphocytic infiltration) and larger islets (≥ 30 endocrine cells/islet). While no difference in the insulin+/glucagon+ cell ratio was found in naïve healthy pancreata from either C57BL/6 or Rip-CD80+GP+ strains (Fig. 6A, left, middle panels), pancreata from diabetic mice displayed a substantial distortion; larger islets displayed an increased insulin+/glucagon+ cell ratio, while small clusters had a decreased ratio (Fig.6A, right panel). A quadratic regression analysis comparing the endocrine-cell-ratio to islet-size relationship is illustrated in more detail in Online Appendix Fig. 2.

We reasoned that the discrepant results shown in Fig. 4A,B (i.e. greater insulin+/glucagon+ dispersed diabetic islet cell ratio by flow cytometry) may have been caused by failure to collect and analyze the exceedingly small, sub-islet-sized endocrine cell clusters from pancreas digests for flow cytometry. To test that possibility, we used flow cytometry to calculate the insulin+/glucagon+ cell ratio from
conventionally purified islets and from an islet-depleted, viable pancreas digest (Fig. 6B-G). While the ratio was comparable in naïve mice (Fig. 6, B-D), diabetic mice demonstrated a marked difference, with purified islets displaying a higher ratio, whereas islet-depleted pancreas digests had a decreased ratio (Fig. 6, E-G). qRT-PCR used to compare the insulin to glucagon mRNA from purified islets and islet-depleted tissue confirmed that the purified islets lost at least as much glucagon compared to insulin mRNA (Online Appendix Fig. 3). The lower abundance of endocrine cells present in islet-depleted pancreas digests suggests that the overall insulin+/glucagon− cell ratio decrease reflects a more precipitous (immune-mediated) β-cell loss outside the confines of traditionally recognized islets, rather than increasing α-cell number. For instance, as illustrated in Online Appendix Fig. 4, we observed that single β-cells or small β-cell clusters were harder to find, nearly always surrounded by inflammatory immune cells in diabetic animals and, unlike in the healthy pancreas, often had glucagon− cells nearby.

Immunofluorescence microscopy of pancreata from mice with recent onset EAD did not establish a consistent loss of β-cells over α-cells, but rather revealed a broad range of relative cell abundances (Online Appendix Table 1). We therefore sought to examine individual mouse pancreata in greater detail. To this end we examined random pancreatic sections from naïve and diabetic EAD mice, previously used for endocrine cell quantification (Fig. 4B,C). In naïve mice, we found the expected β- and α-cell spatial orientation in islets, and uniformly throughout the organ (Fig. 7 A-D). In contrast, the diabetic mouse pancreas analysis displayed marked differences, with two distinct histopathological patterns occurring in the same organ. The first pattern is characterized by scarce, scattered insulin+ cells within infiltrated islets, resulting in near parity of β- and α-cell numbers (Fig. 7 E-H), a pattern consistent with an autoimmune process which selectively destroyed most β-cells, but left α-cells unharmed. The second pattern revealed a similar abundance of insulin-staining cells in severely infiltrated islets along with dramatically reduced glucagon-stained α-cells (Fig. 7 I-L), a finding not easily explained by a β cell-specific deletion process. The two patterns were not randomly distributed within the pancreas, but one or the other pattern predominated in specific anatomical lobes (or lobules) where the vast majority of islets tended to show the same cell pattern.

Finally we sought to address if the observed α-cell loss might have a measurable functional correlate. We tested glucagon serum levels in both fed and fasted mice and in response to 2-DG-induced intracellular hypoglycemia. 2-DG was chosen over insulin-induced hypoglycemia because exogenous insulin can suppress α-cell glucagon secretion (28). Fed and overnight fasted glucagon levels were virtually unchanged and indistinguishable in diabetic mice compared with naive control mice (Fig. 8 left and middle panels). Remarkably, 2-DG-stimulated glucagon secretion was significantly blunted in the diabetic mice (Fig. 8 right panels). 2-DG induced glucagon response could not have been influenced by elevated blood glucose levels because the newly diabetic Rip−CD80+GP+ mice (fed glucose > 20 mM) were restored to normoglycemia after overnight fasting (mean BG 8.5 mM, and consistently negative for fasting urine glucose, Fig. 8 circles), almost certainly reflecting substantial residual β-cell number at this early disease time point. We cannot prove that the α-cell loss we observed at autoimmune diabetes onset and the ~50% reduction of 2-DG-stimulated glucagon secretion are causally related, or whether α-cell regulation of glucagon mRNA and protein synthesis could be a contributing factor. Further careful investigations
including \( \alpha \)-cell gene expression profiles and the application of more sensitive organ perfusion approaches will likely have to determine the exact cause of glucagon pathophysiology frequently observed in autoimmune diabetes.

**DISCUSSION**

This study’s initial objective was to assess pancreatic \( \beta \)-cell numbers and physiology during immune-mediated islet destruction by following the insulin/\( \alpha \)-glucagon \( \alpha \)-cell ratios and other parameters made possible by advanced flow cytometry techniques. We were surprised to observe that the relative frequency of the two endocrine subsets consistently pointed to an unexpected depletion of \( \alpha \)-cells, along with the expected \( \beta \)-cell loss at diabetes onset. It is important to point out that since the flow technique lacks an internal reference standard, one cannot accurately determine the absolute number of \( \alpha \)- or \( \beta \)-cells in the pancreas, only their relative proportion. We therefore turned to immunofluorescence microscopy and quantitative immunohistochemistry, supported by qRTR-PCR, to provide additional, overlapping, and independent techniques. As discussed in our results, all studies supported our initial conclusion that while \( \beta \)-cells are being depleted during autoimmune diabetes, many \( \alpha \)-cells also disappear.

Several lines of thought make it unlikely that non-specific cell mediated cytotoxicity (i.e. bystander injury) caused the observed non-insulin \( \alpha \)+ islet cell (i.e. \( \alpha \)-cell) depletion. One, the insulin-promoter-controlled GP-autoantigen is known to be specifically recognized by the adoptively transferred CTL(18;29), and transgenic CD80 molecules, which are essential for diabetes induction, are expressed homogenously on the transgenic mouse \( \beta \)-cell surface but not on other islet cell types (4). Whether all Rip-GP transgenic \( \beta \)-cells express the GP-transgene product is not known with certainty since detecting GP by immunofluorescence is hampered by mixed intracytoplasmic and nuclear expression patterns and by the limited availability of GP-specific antibodies. The fact that LCM virus infection efficiently induces fulminant diabetes in Rip-GP mice (but never in wild type controls) (30) strongly suggests that the vast majority of \( \beta \)-cells express the antigen leading to their immune mediated destruction. In addition, the large proportion (30-70\%) of the activated, \( \beta \)-cell monospecific, TCR-transgenic CTLs found in EAD model mouse islets at diabetes onset argues in favor of a selective immune-targeting of the Rip-controlled, dominant GP-epitope in \( \beta \)-cells, and does not support T cell epitope-spreading as the underlying autoimmune mechanism. Two, in past studies when we co-transplanted islets expressing the GP along with wild-type islets, only the GP-expressing \( \beta \)-cells were destroyed despite an intense inflammatory infiltrate surrounding all the islets. In this environment non-transgenic islets were left microscopically intact and survived long-term (unpublished results), arguing against an effective inflammation-mediated bystander injury to \( \alpha \)-cells. Three, we have shown differential persistence of endocrine cells located in islets versus sub-islet sized endocrine cell clusters, as well as very different endocrine cell ratios in anatomical parts of the same pancreas with no discernible differences in the severity of immune-cell infiltration. Taking all this data together, we favor a scenario where \( \alpha \)-cell survival is homeostatically regulated in the context of deteriorating glycemia, possibly accompanied by regenerative processes, which may affect distinct anatomical structures (e.g. pancreatic lobes) differently. It is also possible however, that within typically identified islets, \( \alpha \)-cell survival may be dependent upon local \( \beta \)-cell-associated factor(s).

At diabetes onset, while insulin deficiency is axiomatic, abundant evidence suggests that
pancreatic β-cells remain detectable for extended periods after disease diagnosis (31). It remains to be determined if these β-cells persist after diabetes onset and/or are constantly regenerated. Most notably, an endocrine cell regenerative response has been reported to occur in several rodent models by mechanisms involving both β-cell proliferation (32;33) and/or neogenesis (34). Regenerative processes may be further stimulated in the presence of excess glucose (1) and by extensive organ injury (22). Moreover, neogenesis of insulin-producing cells by differentiation from non-β-cell precursors, such as ductal cells, could explain the abundant and scattered immune cell infiltrates we observe at diabetes onset, particularly infiltrates along ductal structures, often distant from any recognizable islet structure. Such regenerative neogenesis may partially or entirely recapitulate embryonic islet cell development (35), and differ among mouse strains. Thus, at present we can only speculate about the possibility that an accelerated β-cell regenerative process stimulated by severe immune-mediated β-cell killing and deteriorating glycemia causes a distorted distribution of other-than insulin + endocrine cells, especially α-cells. In this respect it is important to note that T1DM patients (36), and animals with autoimmune diabetes (37;38), are known to display aberrant glucagon secretory patterns. For instance, while fasting serum glucagon levels are usually normal in T1DM, they paradoxically can increase with overt hyperglycemia (39;40). Further, many patients with T1DM fail to counter-regulate hypoglycemia with adequate glucagon secretion (41;42), reminiscent of our results demonstrating that “intracellular” hypoglycemia-induced glucagon secretion is severely diminished in newly diabetic mice.

Our findings demonstrate that after autoimmune diabetes onset, an endocrine cell’s fate is dynamically regulated, responding to its micro- and macroenvironment. We argue that carefully unraveling the processes underlying autoimmune diabetes will illuminate pancreatic islet endocrine cell subsets’ interdependence, and may shed light on regenerative functions, including islet cell replication and neogenesis, that ultimately exhaust and fail precipitating the onset of autoimmune diabetes.

ACKNOWLEDGEMENTS

The authors like to thank Alice Franks for mouse colony management, Eric Liu and Frank Leopardi for collagenase inflations of mouse pancreas, and Vipul Periwal and Arthur Sherman for regression analysis and critically reading the manuscript. This research was supported by the Intramural Research Program of the NIH, NIDDK.

REFERENCES

3. Valorani MG, Hawa MI, Buckley LR, Afeltra A, Cacciapaglia F, Pozzilli P: The natural history of insulin content in the pancreas of female and male non-obese diabetic mouse:


FIG. 1. Pancreatic islet hormone-secreting cell subsets as assessed by immunofluorescence and flow cytometry. **A:** Pancreas section from a naïve C57BL/6 mouse simultaneously stained for the three major endocrine cell subsets: insulin\(^+\) (β-cells, red), glucagon\(^+\) (α-cells, green), and somatostatin\(^+\) (δ-cells, dark blue). Nuclei are shown in turquoise. Magnification: 400x. **B:** Islet endocrine cells by flow cytometry. Handpicked pancreatic islets isolated from one naïve C57BL/6 mouse were dissociated into a single cell suspension and intracytoplasmically stained for insulin (red), glucagon (green), and somatostatin (blue). All other islet components (e.g. other endocrine, endothelial cells) and residual exocrine cells are depicted in grey. For presentation purposes, insulin\(^+\), glucagon\(^+\), and somatostatin\(^+\) endocrine cell subsets (typically making up approx. 80% of healthy islets) were normalized to 100%. **C:** Quantitative analysis of islet cell subsets of naïve C57BL/6 mice by flow cytometry (black bars) and immunofluorescence (grey bars). For flow cytometry, greater than 10,000 events of dissociated, and stained islet cells per mouse were acquired. Frequencies (mean±SEM, n=5 mice) were: insulin\(^+\) 73.5±2.4%; glucagon\(^+\) 19.2±1.9%; somatostatin\(^+\) 5.5±0.6%; and pancreatic polypeptide\(^+\) 1.7±0.5%. For immunofluorescence, the three major endocrine cell subsets were quantified by independent, triplicate or quadruplicate scorings (>350 endocrine cells were counted out of at least 12 randomly selected islets). Their frequencies (mean±SEM, n=3 mice) were 76.7±1.1%, 17.3±3.3%, and 5.9±4.0% for insulin\(^+\), glucagon\(^+\), and somatostatin\(^+\) cells, respectively.
FIG. 2  Diabetic mouse β cell optical changes by flow cytometry.  A: Light scatter properties (cell size, FSC, and granularity, SSC) of dissociated islet cells (red, β-cells; green, α-cells; blue, δ-cells) from naive and diabetic mice are shown.  β-cell size distribution differs between naive and diabetic mice.  B: Side scatter (SSC, granularity) properties of naive and diabetic islet cells gated on insulin-stained cells, displayed by histogram overlay and quantified by median side scatter signal.  C: Insulin-staining brightness (median fluorescence intensity) of naive and diabetic β-cells is compared, and plotted by histogram overlay and fold increase over non-insulin+ islet cells (background staining).
FIG. 3. Comparative analysis of naïve and diabetic pancreatic islets by immunofluorescence and flow cytometry. Islets from naïve (A-C) and recently diabetic mice (D-F) were examined by tissue sectioning and H&E staining (A,D; magnification: 200x), and 3-color immunofluorescence (B,E; magnification: 400x). Typical islets are shown (A-B, D-E). In addition, islets from an individual naïve or diabetic mouse were purified, dissociated and analyzed by flow cytometry (C,F). Flow cytometry results were normalized as in Fig.1. F: The drastically increased unstained cells (events shown in grey) represent cells within the islets that did not stain for any of the three islet hormones, insulin, glucagon, or somatostatin, nor for the hematopoetic cell marker CD45, which had been excluded by electronic gating. Thus, these cells represent islet cell components relatively enriched in inflamed, severe endocrine cell-depleted islets. Note that the relative frequency of insulin$^+$ cells did not decrease compared to glucagon$^+$ cells and in this case only marginally compared to somatostatin$^+$ cells.
FIG. 4. Endocrine cell quantification using flow cytometry and quantitative immunohistochemistry. Pancreata from naïve (grey symbols) and diabetic EAD mice (black) were examined by A: multicolor flow cytometry, and B: immunofluorescence microscopy. Insulin⁺/glucagon⁺ cell ratios were plotted with each symbol representing an individual mouse. Vertical bars indicate the arithmetic means for groups of mice; they were for A: 4.9, 9.8; and B: 4.9, 4.2. Note, that purified, handpicked islets were used for flow cytometry in A, whereas in B: all microscopically detectable insulin- or glucagon-stained cells were scored. C: β-cell mass, and D: α-cell mass from naïve (n=5) and diabetic (n=4) EAD mice (C,D, panels’ left sides) and groups of age-matched NOD-Rag2-null (n=3) and diabetic NOD mice (n=4; C,D, panels’ right sides) were determined by image analysis of insulin or glucagon immunohistochemistry. Each symbol represents the cumulative fractional cell mass per pancreas, and the errors bar indicate the SEM of 3-7 individual sections per pancreas. Differences in diabetic and naïve control pancreata were all found to be statistically significant (p<0.001, except for glucagon⁺ cell loss in NOD mice[p= 0.026]).
FIG. 5 Analysis of purified NOD islet cell suspensions by flow cytometry. A 23-week-old, non-diabetic (upper panel), a 15-week-old newly diabetic female NOD mouse (middle panel), and a 18-week-old NOD-SCID is shown (lower panel). Gating strategy involved consecutively light scatter (left column), exclusion of CD45+ lymphocytes (center column), doublet exclusion (not shown), and relative frequencies of insulin+ β-cells vs glucagon+ α-cells (right panels). The β- to α-cell ratio of ~4 in both representative non-diabetic mice (average non-diabetic NOD β- to α-cell ratio was 3.4±0.5, n=7, and 4.0±0.2, n=3 for NOD-SCIDs) dropped to 1.8 in the diabetic NOD mouse (average for this group: 1.3±0.3, n=7) due to a more profound loss in the β-cell compartment. Infiltrating CD45+ lymphocytes were absent in NOD-SCID islets, but plenty were found in isolated islets of both NOD mice, being more abundant in the diabetic animal. Note the decreased β-cell granularity reflected by a low side scatter in all NOD mice shown, indicating possibly fewer or less-developed insulin granules in this mouse strain even in the absence of immune-mediated organ injury in NOD-SCID mice (left column, lower panel). Granulatity seemed further reduced as the mice progressed towards autoimmune diabetes (left column, top and middle panels).
FIG. 6. Quantification of endocrine cells in large islets or sub-islet sized endocrine clusters of
A: Relative abundance by immunofluorescence histology of β- and α-cells associated with islets
or sub-islet-sized endocrine clusters in naïve and recently diabetic mice. Endocrine cells were
counted from sections, and subdivided in groups of small-endocrine cell clusters (<30 endocrine
cells per cross section, open bars), or large islets (≥30 endocrine cells per cross section, grey
bars), and the sum of both (all islets, black bars). The insulin⁺/glucagon⁺ cell ratio of naïve
C57BL/6 (left panel, n=3), naïve and diabetic Rip-CD80+GP+ mice (middle panel, n=3, and
right panel, n=5, respectively) was plotted for each islet size group. Insulin⁺, glucagon⁺, and
somatostatin⁺ cell frequencies by flow cytometry in different pancreas compartments and from
both naïve and recently diabetic mice. Purified islet cells (B,E), and viable, islet-depleted
pancreatic tissue (C,F) were isolated from naïve (upper panel) and diabetic mice (lower panel).
Representative flow cytometry plots and the calculated relative frequency of endocrine cell
subsets are shown. D: The averages of insulin⁺/glucagon⁺ cell ratios among islets and islet-
depleted tissue (containing the small endocrine cell clusters) from healthy (n=4) and diabetic
mice (n=3, G).
FIG. 7. Anatomical location within the pancreas determines the endocrine cell fate during diabetes development. Consecutive sections of a naive (A-D) and one newly diabetic (E-L) RipCD80+GP+ mouse were analyzed for insulin- (left panel) and glucagon staining by immunohistochemistry (right panel). The naive pancreas showed the expected abundance and spatial orientation of β- and α-cells in virtually all islets examined. Representative islets (inset) are shown with higher magnification (B,D). Groups of diabetic islets (arrowheads, depicted on glucagon-stained sections only) are shown from different lobes of the same pancreas (E,G and I,K), and with higher magnification (F,H and J,L). Note the uniform pattern of endocrine islet cell abundance in neighboring groups of islets.
FIG. 8. Recently diabetic mice display lower secretory glucagon responses to 2-DG induced intracellular hypoglycemia. Blood glucose (circles) and serum glucagon levels from naive (grey bars) and diabetic Rip-CD80+GP+ mice (black bars) were determined in random fed (left panel, n=7, and 4 for naive and diabetic mice, respectively), overnight fasted mice (middle panel, n=16, and 8), and after 2-DG stimulation (right panel, n=15, and 7). Serum glucagon levels are given as mean ± SEM. * p<0.003.